PhD Thesis_ver3.pdf

Сравнително in vitro изследване на нови възможности за фармакологично повлияване на
мултипления миелом
55. Dorlo, T. P., P. P. van Thiel, A. D. Huitema, R. J. Keizer, H. J. de Vries, et al. (2008).
"Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients." Antimicrob
Agents Chemother 52(8): 2855-60.
56. Doss, D. S. (2006). "Advances in oral therapy in the treatment of multiple myeloma." Clin J Oncol
Nurs 10(4): 514-20.
57. Drexler, H. G. (2001). The leukemia-lymphoma cell line : factsbook. San Diego, Calif., Academic
Press.
58. Durie, B. G. and S. E. Salmon (1975). "A clinical staging system for multiple myeloma. Correlation
of measured myeloma cell mass with presenting clinical features, response to treatment, and
survival." Cancer 36(3): 842-54.
59. Durie, B. G., D. Stock-Novack, S. E. Salmon, P. Finley, J. Beckord, et al. (1990). "Prognostic value of
pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study."
Blood 75(4): 823-30.
60. Efferth, T., U. Fabry and R. Osieka (2002). "Interleukin-6 affects melphalan-induced DNA damage
and repair in human multiple myeloma cells." Anticancer Res 22(1A): 231-4.
61. Eibl, H., D. Arnold, H. U. Weltzien and O. Westphal (1967). "[On the synthesis of alpha and beta
lecithins and their ether analogs]." Justus Liebigs Ann Chem 709: 226-30.
62. Eibl, K. H., B. Banas, C. L. Schoenfeld, C. A. May, A. S. Neubauer, et al. (2003).
"Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells." Invest
Ophthalmol Vis Sci 44(8): 3556-61.
63. Eibl, K. H., D. Kook, S. Priglinger, C. Haritoglou, A. Yu, et al. (2006). "Inhibition of human retinal
pigment epithelial cell attachment, spreading, and migration by alkylphosphocholines."
Invest Ophthalmol Vis Sci 47(1): 364-70.
64. Eibl, K. H., G. P. Lewis, K. Betts, K. A. Linberg, A. Gandorfer, et al. (2007). "The effect of
alkylphosphocholines on intraretinal proliferation initiated by experimental retinal
detachment." Invest Ophthalmol Vis Sci 48(3): 1305-11.
65. Erdlenbruch, B., V. Jendrossek, A. Gerriets, F. Vetterlein, H. Eibl, et al. (1999).
"Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat
after intravenous administration." Cancer Chemother Pharmacol 44(6): 484-90.
66. Fang, J., J. Lu and A. Holmgren (2005). "Thioredoxin reductase is irreversibly modified by
curcumin: a novel molecular mechanism for its anticancer activity." J Biol Chem 280(26):
25284-90.
67. Fauci, A. S. and T. R. Harrison (2008). Harrison's principles of internal medicine. New York ;
London, McGraw-Hill Medical.
68. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, et al. (1998). "Identification
of a novel inhibitor of mitogen-activated protein kinase kinase." J Biol Chem 273(29): 18623-
32.
69. Feinman, R., J. Koury, M. Thames, B. Barlogie, J. Epstein, et al. (1999). "Role of NF-kappaB in the
rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2." Blood
93(9): 3044-52.
70. Fichtner, I., R. Zeisig, H. Naundorf, S. Jungmann, D. Arndt, et al. (1994). "Antineoplastic activity of
alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of
liposomes." Breast Cancer Res Treat 32(3): 269-79.
71. Fiegl, M., L. H. Lindner, M. Juergens, H. Eibl, W. Hiddemann, et al. (2008). "Erufosine, a novel
alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other
antileukemic drugs." Cancer Chemother Pharmacol 62(2): 321-9.
72. Fleer, E. A., C. Unger, D. J. Kim and H. Eibl (1987). "Metabolism of ether phospholipids and
analogs in neoplastic cells." Lipids 22(11): 856-61.
73. Fogh, J. (1975). Human tumor cells in vitro. New York, Plenum Press.
74. Folmer, F., R. Blasius, F. Morceau, J. Tabudravu, M. Dicato, et al. (2006). "Inhibition of TNFalphainduced
activation of nuclear factor kappaB by kava (Piper methysticum) derivatives."
Biochem Pharmacol 71(8): 1206-18.
314